Cargando…
Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the det...
Autores principales: | Solar Vasconcelos, Joao Paulo, Boutin, Melina, Loree, Jonathan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772953/ https://www.ncbi.nlm.nih.gov/pubmed/36570410 http://dx.doi.org/10.1177/17588359221143975 |
Ejemplares similares
-
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
por: Boutin, Mélina, et al.
Publicado: (2023) -
Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma
por: Topham, James T., et al.
Publicado: (2023) -
Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?
por: Piercey, Oliver, et al.
Publicado: (2023) -
Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors –
can we RECIST? Focus on colorectal cancer
por: Spindler, Karen-Lise Garm, et al.
Publicado: (2023) -
Association between circulating tumor cells in the peripheral blood and the prognosis of gastric cancer patients: a meta-analysis
por: Jin, Tao, et al.
Publicado: (2023)